Brief: Crossject Announces Successful Completion Of Final Validation Study Of Zeneo Midazolam
12/09/2022 17:19
Sept 12 (Reuters) - Crossject SA 74C.F :
* ANNOUNCES THE SUCCESSFUL COMPLETION OF FINAL VALIDATION
STUDY OF
ZENEO® MIDAZOLAM
Source text for Eikon: ID:nGNE6Vr349
Further company coverage: 74C.F
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Crossject SA
See all newsBrief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure